Victory Capital Management Inc. Boosts Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Victory Capital Management Inc. lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 6.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,494 shares of the company’s stock after buying an additional 1,588 shares during the quarter. Victory Capital Management Inc.’s holdings in Roivant Sciences were worth $325,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. TOMS Capital Investment Management LP acquired a new position in Roivant Sciences during the third quarter worth $46,333,000. FMR LLC raised its holdings in Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after purchasing an additional 2,593,910 shares during the last quarter. Geode Capital Management LLC raised its holdings in Roivant Sciences by 23.2% during the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after purchasing an additional 1,460,205 shares during the last quarter. State Street Corp raised its holdings in Roivant Sciences by 6.1% during the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after purchasing an additional 1,118,561 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Roivant Sciences by 49.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company’s stock worth $26,625,000 after purchasing an additional 762,953 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on ROIV. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $18.08.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the purchase, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00. Following the completion of the transaction, the chief operating officer now owns 896,869 shares of the company’s stock, valued at $9,551,654.85. The trade was a 10.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,875,586 shares of company stock valued at $21,491,661 over the last three months. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Stock Down 1.6 %

NASDAQ ROIV opened at $10.79 on Friday. Roivant Sciences Ltd. has a fifty-two week low of $9.93 and a fifty-two week high of $13.06. The stock has a market cap of $7.70 billion, a price-to-earnings ratio of -71.93 and a beta of 1.26. The business has a fifty day moving average of $10.78 and a 200-day moving average of $11.46.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.